| Revised international prognostic scoring system for myelodysplastic syndromes PL Greenberg, H Tuechler, J Schanz, G Sanz, G Garcia-Manero, F Solé, ... Blood, The Journal of the American Society of Hematology 120 (12), 2454-2465, 2012 | 3310 | 2012 |
| New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients D Haase, U Germing, J Schanz, M Pfeilstöcker, T Nösslinger, ... Blood, The Journal of the American Society of Hematology 110 (13), 4385-4395, 2007 | 1042 | 2007 |
| New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international … J Schanz, H Tüchler, F Solé, M Mallo, E Luño, J Cervera, I Granada, ... Journal of Clinical Oncology 30 (8), 820, 2012 | 827 | 2012 |
| Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference P Valent, HP Horny, JM Bennett, C Fonatsch, U Germing, P Greenberg, ... Leukemia research 31 (6), 727-736, 2007 | 730 | 2007 |
| Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions P Valent, A Orazi, DP Steensma, BL Ebert, D Haase, L Malcovati, ... Oncotarget 8 (43), 73483, 2017 | 217 | 2017 |
| Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary … U Germing, B Hildebrandt, M Pfeilstöcker, T Nösslinger, P Valent, ... Leukemia 19 (12), 2223-2231, 2005 | 216 | 2005 |
| Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution T Nösslinger, R Reisner, E Koller, H Grüner, H Tüchler, H Nowotny, ... Blood, The Journal of the American Society of Hematology 98 (10), 2935-2941, 2001 | 203 | 2001 |
| Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the … J Schanz, C Steidl, C Fonatsch, M Pfeilstöcker, T Nösslinger, H Tuechler, ... Journal of clinical oncology 29 (15), 1963, 2011 | 188 | 2011 |
| Time-dependent changes in mortality and transformation risk in MDS M Pfeilstöcker, H Tuechler, G Sanz, J Schanz, G Garcia-Manero, F Solé, ... Blood, The Journal of the American Society of Hematology 128 (7), 902-910, 2016 | 179 | 2016 |
| Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System … MG Della Porta, H Tuechler, L Malcovati, J Schanz, G Sanz, ... Leukemia 29 (7), 1502-1513, 2015 | 166 | 2015 |
| Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q M Mallo, J Cervera, J Schanz, E Such, G García-Manero, E Luno, C Steidl, ... Leukemia 25 (1), 110-120, 2011 | 160 | 2011 |
| Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del (5q): a multicenter study U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, ... Leukemia 26 (6), 1286-1292, 2012 | 149 | 2012 |
| ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016 C Dittrich, M Kosty, S Jezdic, D Pyle, R Berardi, J Bergh, N El-Saghir, ... ESMO open 1 (5), e000097, 2016 | 133 | 2016 |
| Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group WR Sperr, F Wimazal, M Kundi, C Baumgartner, T Nösslinger, A Makrai, ... Annals of oncology 21 (1), 114-119, 2010 | 133 | 2010 |
| Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis G Greiner, B Sprinzl, A Górska, F Ratzinger, M Gurbisz, N Witzeneder, ... Blood, The Journal of the American Society of Hematology 137 (2), 238-247, 2021 | 126 | 2021 |
| Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions P Valent, A Orazi, MR Savona, MM Patnaik, F Onida, ... haematologica 104 (10), 1935, 2019 | 125 | 2019 |
| Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma H Kaufmann, J Ackermann, C Baldia, T Nösslinger, R Wieser, S Seidl, ... Leukemia 18 (11), 1879-1882, 2004 | 106 | 2004 |
| Preanalytic removal of human DNA eliminates false signals in general 16S rDNA PCR monitoring of bacterial pathogens in blood M Handschur, H Karlic, C Hertel, M Pfeilstöcker, AG Haslberger Comparative immunology, microbiology and infectious diseases 32 (3), 207-219, 2009 | 103 | 2009 |
| Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics M Pfeilstöcker, R Reisner, T Nösslinger, H Grüner, H Nowotny, H Tüchler, ... British journal of haematology 106 (2), 455-463, 1999 | 102 | 1999 |
| Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia C Sillaber, M Mayerhofer, A Böhm, A Vales, A Gruze, KJ Aichberger, ... European journal of clinical investigation 38 (1), 43-52, 2008 | 91 | 2008 |
